Two new analogues of lidocaine were synthesized at the College of Pharmacy, King Saud University: compound I (Methyl-2-[2-(N,N-diethylamino) acetamido]-3-cyano-4,5-dimethylbenzoate) and compound II (Methyl-2-[2-(piperidino) acetamido]-3-cyano-4,5-dimethylbenzoate). Their influence on the arterial blood pressure and the heart rate of urethane-anaesthetized rats was studied and compared with the actions of lidocaine. Compounds I, II and lidocaine induced significant dose-dependent decreases in the arterial blood pressure and heart rate, which usually returned to basal values within 3-5 min. There were significant differences in the potency of the three compounds in producing their effects on blood pressure and heart rate (P < 0.0001, ANOVA). Compound II was 14 and 6 times more potent in reducing blood pressure and 8 and 2 times more capable of reducing the heart rate than lidocaine and compound I, respectively. The results of this study also indicated the ineffectiveness of antagonists of autonomic, histaminergic and 5-HT receptor, and various vasodilators in blocking the actions of the three compounds on blood pressure and heart rate. Pretreatment with CaCl 2 significantly reduced the hypotension and bradycardia induced by the three compounds, suggesting the involvement of calcium channels, probably of the L type. Several possible mechanisms are postulated. In conclusion, the results direct attention to the capability of the two new compounds to decrease blood pressure and heart rate; affects that may have clinical potential.
INTRODUCTION
Lidocaine hydrochloride is an aminoethylamide derivative that is used clinically as a local anaesthetic and a class-IB antiarrhythmic agent. Lidocaine suppresses fast inward sodium currents, thereby depressing the maximum rate of cellular depolarization [1] . Furthermore, specific interactions of lidocaine with K + channels, Ca 2+ channels, [2] and rynodine receptors/Ca 2+ releasing channels [3] were reported. Despite the clinical usefulness of lidocaine, its use is associated with several side effects such as drowsiness, agitation, paresthesia, bradycardia and hypotension and in toxic doses predisposition to convulsions and respiratory depression [4] . Therefore, a search for more efficient analogues may be of great value in clinical practice. This prompted Al-Obaid [5] to synthesize two novel analogues of lidocaine: compound * Corresponding author. E-mail: abno2000@hotmail.com.sa I (Methyl-2-[2-(N,N-diethylamino) acetamido]-3-cyano-4,5-dimethylbenzoate) and compound II (Methyl-2-[2-(piperidino) acetamido]-3-cyano-4,5-dimethylbenzoate). Al Obaid [5] demonstrated that both compounds exhibited significant local-anaesthetic activity. Furthermore, a thorough study of other pharmacological actions of these two compounds was undertaken in a series of consecutive experiments. This paper will deal with the influence of compounds I and II on the arterial blood pressure and heart rate of urethane-anaesthetized rats, and will compare the observed effects with that of lidocaine. Attempts will also be made to elucidate the general mechanism(s) underlying the observed effects. Lidocaine was found to possess a hypotensive effect [6] [7] [8] which is sometimes observed clinically during the course of its use as an antiarrhythmic agent. It would be of interest, and possibly of therapeutic value, to discover whether these two analogues affect the cardiovascular system. Effect of compound II on the arterial blood pressure and heart rate of a urethane-anaesthetized rat. Compound I was administered i.v. (2-64 µg kg −1 ). The 40 s scale represents the normal recording speed (0.5 mm s −1 ) whereas the 2 s scale represent the speed of recording following its increase from 0.5 to 10 mm s −1 to enable the heart rate to be counted. The vertical mm Hg scale represents the calibration scale used to quantify the drug-induced decreases in the arterial blood pressure in mm Hg. The following drugs/chemicals were also utilized: lidocaine hydrochloride (ASTRA Pharmaceuticals); urethane and CaCl 2 (BDH, UK); L-NAME (N w -nitro-L-arginine methyl ester hydrochloride), ranitidine hydrochloride, cyproheptadine and mepacrine hydrochloride, (Sigma Chemical Co., USA); indomethacin sodium confortid (Dumex Ltd., Denmark); propranolol hydrochloride (ICI, UK); mepyramine maleate (Drug Pharmaceutical Trading, B.U. Holland) and hexamethonium bromide (KOCK-Light Laboratories Ltd., UK). All chemicals were dissolved in distilled water.
MATERIALS AND METHODS

Drugs
Preparation of rats for measurement of arterial blood pressure and heart rate
Male Wistar rats (200-250 g) were anaesthetized using urethane (1000 IU kg −1 ). The arterial blood pressure and heart rate in the rats were measured afterwards as described by El Tahir et al. [9] . The right-external jugular vein and the left-carotid artery were exposed and cannulated for administration of drugs and recording of the arterial blood pressure, respectively. Arterial blood pressure was measured using a strain gage coupler attached to a physiograph (Narco, MK1-V-P, Narco Biosystems, Houston, USA) with a built-in calibration system for quantification of blood pressure in mm Hg. The change in arterial blood pressure was obtained by subtracting the maximum decrease reached from basal values. The heart rate was calculated by increasing the speed of recording from 0.5 to 10 mm s −1 for 10 s and multiplying the number of beats during that period by 6 (beats per min). Changes in the heart rate were calculated as the percentage change from pre-drug levels. Pilot studies were undertaken to determine appropriate doseresponse curves so as to choose doses with equipotent effects. Each chosen dose for compound I (13, 26, 52, 78, 104 and 130 µg kg −1 ), compound II (2, 4, 8, 16, 32 and 64 µg kg −1 ), and lidocaine (40, 80, 120, 160, 200, 240 and 280 µg kg −1 ) were flushed in with 0.2 ml normal saline and subsequent doses were administered at 5 min intervals: a time usually sufficient for arterial blood pressure to return to its basal value. One dose-response curve was recorded for each animal.
Effect of receptor blockers, enzyme inhibitors and CaCl 2
To examine the influence of receptor blockers and enzyme inhibitors on the test compounds/lidocaine-induced changes in arterial blood pressure and heart rate, each was administered 5 min (in case of the receptor blockers) or 30 min (in case of enzyme inhibitors) prior to the administration of test compounds/ lidocaine. The doses used in this study were calculated according to the methods of Paget and Barnes [10] and were as follows (IV): atropine (1 mg kg −1 ), propranolol (1 mg kg −1 ), hexamethonium (2.5 mg kg −1 ), mepyramine (1 mg kg −1 ), ranitidine (10 mg kg −1 ), cyproheptadine (1 mg kg −1 ), L-NAME (25 mg kg −1 ), mepacrine (40 mg kg −1 ) and indomethancin (20 mg kg −1 ). Six animals were used to test a single blocker/inhibitor. To examine the influence of CaCl 2 on the test compounds/lidocaineinduced changes, a 10% aqueous solution of CaCl 2 was administered slowly (60 mg kg −1 , IV), 5 min after a submaximal dose (IV) of test compound/lidocaine; the submaximal doses were then repeated 5 min after the CaCl 2 administration. The percentage effectiveness of CaCl 2 in antagonizing these effects was then calculated as follows: drug-induced change before Ca 2+ −change after Ca 2+ /change before Ca 2+ (percentage change in the case of heart rate).
Statistical analysis
Results are expressed as arithmetic mean ± standard error of the mean (SEM). The statistical significance in the case of repeated measurements within an individual animal, before and after drug administration, was evaluated by a paired Student's t-test. Values of P ≤ 0.05 were considered significant.
RESULTS
Blood pressure and heart rate recording in anaesthetized rats
In control experiments, anaesthetized saline-treated rats (0.9% sodium chloride, 0.25 ml kg −1 , i.v., n = 5) showed no significant changes from the resting values in mean arterial blood pressure (95 ± 3 mm Hg) and heart rate (285 ± 11.8 beats per min) throughout the experiment.
Effect of compounds I, II and lidocaine on the arterial blood pressure and heart rate of rats
In general, intravenous administration of compounds I, II, or lidocaine into the urethane-anaesthetized rats induced significant, dose-dependent decreases in arterial blood pressure and heart rate. Figures 1-3 show examples of typical experiments following administration of different doses of compounds I, II and lidocaine. The changes in both heart rate and arterial blood pressure usually returned to basal values within 3-5 min. Figures 4 and 5 represent the average decrease in blood pressure (mm Hg) and the percentage reduction in heart rate, respectively, following the administration of graded doses of the three compounds. To facilitate the comparison between them, the dose that decreased the blood pressure 30 mm Hg from the baseline value in each individual animal was calculated and tabulated as presented in Table I (30 mm Hg was usually mid-range). Furthermore, the dose that produced 50% of the maximum reduction in heart rate was calculated for each individual animal and tabulated (Table I) .
Effect of receptor blockers and enzyme inhibitors on compounds I-, II-and lidocaine-induced cardiovascular depressant effects
Treatment of the rats with either atropine, hexamethonium, mepyramine, ranitidine, cyproheptadine, L-NAME, mepacrine, or indomethacin did not antagonize the compounds I-, II-and lidocaine-induced cardiovascular depressant effect to any significant level. However, treatment of the rats with propranolol (1 mg kg −1 for 5 min) before administration of lidocaine (but not compounds I and II) enhanced the hypotensive effect of lidocaine by 60 ± 6.81% ( * P < 0.05, n = 6). 
Effects of CaCl 2 on compounds I-, II-and lidocaine-induced cardiovascular depressant actions
Treatment of rats with CaCl 2 (60 mg kg −1 ) for 3 min suppressed the effects of submaximal doses of compounds I (52 µg kg −1 ), II (32 µg kg −1 ) and lidocaine (120 µg kg −1 ). In eight such experiments CaCl 2 antagonized compounds I-, II-and lidocaineinduced decrease in the arterial blood pressure by 39.71± 5.94%, 80 ± 16% and 53.57 ± 4.86%, respectively.
However, the percentage decrease in the heart rate induced by compounds I, II and lidocaine before administration of CaCl 2 were 47.1 ± 5.6%, 63.6 ± 14.5% and 34.34 ± 11.45%, respectively, while the corresponding values in case of compounds I, II and lidocaine after treatment of rats with CaCl 2 were 29.41 ± 6.1%, 42.86 ± 9.7% and 8.2 ± 1.21%, respectively. A typical example is presented in Fig. 6 and values are tabulated in Tables II and III .
DISCUSSION
The two newly synthesized lidocaine analogues, compounds I and II, were capable of decreasing both the blood pressure and heart rate of anaesthetized rats. These effects were also observed in the parent compound 'lidocaine', which is in agreement with the cardiovascular depressant effects observed by Hogan et al. [11] and Nelson and Hoffman [12] . Although compounds I and II were synthesized with the hope of avoiding some of the known lidocaine side effects the results of this study showed that both of them mimicked lidocaine in terms of two major side effects, namely a decrease in the arterial blood pressure and heart rate. However, it is hoped that further studies may reveal differences in the other potential side effects involving the respiratory and the central nervous system; especially since the two compounds seemed to be more potent than lidocaine and can therefore be used in smaller doses.
The effects of the test compounds and lidocaine, on the blood pressure and heart rate, were not inhibited after pretreatment with antagonists of muscarinic receptors (atropine), ganglionic nicotine receptors (hexamethonium), histaminergic H 1 and H 2 receptors (mepyramine and ranitidine), serotoninergic receptors (cyproheptadine), phospholipase A 2 (mepacrine), cyclooxygenase (indomethancin), or nitric oxide synthase (L-NAME). This would indicate that these compounds, in the doses used, do not appear to elicit these actions via activation of muscarinic, nicotinic, histaminergic or serotoninergic receptors, or through release of the vasodilators prostaglandins, platelet activating factors or nitric oxide. Roden [13] stated that theoretically lidocaine has no significant interaction with the autonomic nervous system and does not appear to affect the histaminergic or serotoninergic systems. However, although propranolol treatment did not inhibit the hypotensive effect of lidocaine it enhanced lidocaine-induced hypotension. Such enhancement may be due to the known actions of propranolol such as the ability of the drug to antagonize the sympathetic reflexes evoked via the baroreceptors as a result of lidocaine-induced hypotension and its ability to block presynaptic β 2 -adrenoceptors involved in activation of noradrenaline release from the adrenergic neurons [14] .
The failure of propranolol to enhance the hypotensive effect of compounds I and II may be due to an inherent property of these compounds such as their ability to enhance the sensitivity of the baroreceptors and/or their ability to activate β 2 presynaptic adrenoceptors. Both actions can mask any enhancement induced by propranolol. Further experiments can reveal the actual cause.
On the other hand, pretreatment with calcium chloride succeeded in significantly reducing the hypotension and bradycardia induced by the three compounds. This finding suggests that these compounds may produce their effects through blockade of calcium channels, probably the slow kinetic 'L' type, an important mediator of extracellular to intracellular calcium flux [15] . In vascular smooth muscle and cardiac muscle cells, the major inward calcium current (involved in excitationcontraction coupling) is through the L-type slow calcium channels [16] [17] [18] . Furthermore, it seems that the lidocaine evoked myocardial depression and vasodilator effect may possibly occur due to: limitation of calcium movement across the sarcoplasmic reticulum [19] , interaction with ryanodine receptors/calcium release channels [20] , interaction with surface calcium binding sites on phospholipids [21] , and/or interaction with calcium, sodium or potassium channels [2, 22] .
In conclusion, the results of this study revealed the ability of the two lidocaine analogue compounds I and II to possess, beside their local anaesthetic effect, an inherent property of decreasing the arterial blood pressure and heart rate and seemed to be more potent than lidocaine in this aspect. Further studies with regard to arrhythmias and local anaesthetic activities can provide a clue to the direction of the potential clinical usefulness of these compounds either as hypotensive, antiarrhythmic or local anaesthetic agents.
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